TSLA
Tesla
-- 454.101 NVDA
NVIDIA
-- 140.090 RGTI
Rigetti Computing
-- 14.5250 PLTR
Palantir
-- 82.405 LAES
SEALSQ Corp
-- 8.680 
NEWS
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.
The presentations include:
Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human
The presentations include:
Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment